O’RIGHT
18.11.2020 10:02:09 CET | Business Wire | Press release
As the novel coronavirus spreads across the world, Taiwanese green beauty brand O’right continues to make significant strides in sustainability. This year, O’right made headlines with the opening of its store in Isetan Shinjuku, a leading department store in Japan. Now, the pioneering brand has made its way into Lyko, a Sweden-based beauty and hair care chain that has quickly become the Nordic region’s leading player in the segment. Recently, the green innovator celebrates the Good Design Gold Award (Japan’s Good Design Award is one of the top 4 design awards in the world) honor for its latest innovation – the world’s greenest toothpaste – to offer new green lifestyle solutions worldwide. O’right continues its commitment to doing what’s best for people, the society and earth and calls on businesses and people to follow suit. What started as a small, unknown name in Taiwan has now evolved into a zero carbon beauty brand that is taking the beauty sector by storm.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005486/en/
A visionary brand that’s here to stay
O’right and the Swedish beauty retailer Lyko first crossed paths at Cosmoprof Bologna. Founded in the world’s most sustainable country, Lyko partners with brands and stocks products that align with its own values and meets its high standards. O’right has been leading the way to sustainability for years, from its innovative 8 Free standard for creating non-toxic, clean and multi-award-winning range of green products to recently receiving the USDA Certified Biobased Product Label. This year, the company aims to achieve zero carbon (carbon neutrality) for 77 of its products. O’right’s commitment to sustainability is shown not only in its values, but also from product formulations to packaging. The trailblazer demonstrates a positive social and environmental impact and powerful visionary narratives that justify its worth and inspire the Swedish-based chain to wholeheartedly invest in. It’s safe to say that the cosmetic world is excited to watch as the partnership between two companies that share the same values from the East and the West blossoms into something incredible.
Green without borders
Lyko boasts Sweden’s largest e-commerce site with an average monthly traffic count of 4 million visits, along with 37 physical stores in Sweden and Norway. Lyko joins forces with O’right, opening the door for the Taiwanese brand to make its green values and products seen in the Nordic region. O’right green products even made it into the e-commerce platform’s top sellers list. As a green zero carbon brand, O’right believes that the key to making a greater influence in every part of the world is to inspire green living and consumption. When it comes to sustainability, distance and national borders don’t matter.
Does O’right, a small Taiwanese company from the small land of Taiwan, have what it takes to conquer the eco beauty sector of the Nordic region? O’right is determined to show its green value and wow consumers with its holistic green lifestyle solutions and innovative trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005486/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom